Division of Urologic Surgery, Duke University Medical Center, Durham, NC.
Urology. 2013 Oct;82(4):933-6. doi: 10.1016/j.urology.2013.06.017. Epub 2013 Aug 1.
To describe our experience with the UroLume Urethral Stent, showing that it provides a viable option for the devastated, obstructed outlet after prostate cancer treatment.
We conducted an institutional review board-approved retrospective study of all men at our facility who underwent placement of the UroLume stent from January 2001 to January 2012. Records were reviewed for patient demographics, outcomes, and complications. We specifically evaluated urinary continence, ingrowth of the UroLume stent, need for repeat operations, and complications related to this treatment including artificial urinary sphincter (AUS) erosion.
Forty-five men underwent placement of the UroLume stent with an average follow-up of 55.8 months. Of these, 41 had simultaneous or subsequent placement of an AUS with an overall continence rate of 35 of 45 (78%). Ingrowth was seen in 16 of 45 (36%) and AUS erosion in 8 of 41 (19.5%). Of the 16 patients treated for ingrowth, the average number of treatments was 2.7 per patient. There was no association between treatment for ingrowth and rate of AUS erosion (P = .92).
Although no longer commercially available, our long-term data indicate that the UroLume was a reasonable minimally invasive treatment option for the devastated, obstructed outlet providing a reasonable rate of need for subsequent interventions. The UroLume maintains patency of the urethral lumen, which usually results in incontinence, but this can be managed with placement of the AUS. The alternative open operative reconstructive options have similar limitations with possibly greater morbidity.
描述我们使用 UroLume 尿道支架的经验，表明它为前列腺癌治疗后受损、梗阻的出口提供了一种可行的选择。
我们对 2001 年 1 月至 2012 年 1 月在我们机构接受 UroLume 支架置入的所有男性进行了一项机构审查委员会批准的回顾性研究。对患者人口统计学数据、结果和并发症进行了回顾。我们特别评估了尿控、UroLume 支架的内生长、重复手术的需求以及与这种治疗相关的并发症，包括人工尿道括约肌（AUS）侵蚀。
45 名男性接受了 UroLume 支架置入，平均随访 55.8 个月。其中 41 例同时或随后置入 AUS，总尿控率为 45 例中的 35 例（78%）。45 例中有 16 例（36%）出现内生长，41 例中有 8 例（19.5%）出现 AUS 侵蚀。在 16 例接受内生长治疗的患者中，平均每位患者的治疗次数为 2.7 次。内生长治疗与 AUS 侵蚀率之间无相关性（P=0.92）。
尽管 UroLume 已不再商业化，但我们的长期数据表明，UroLume 是一种合理的微创治疗选择，适用于受损、梗阻的出口，后续干预的需求率合理。UroLume 保持尿道管腔通畅，通常会导致尿失禁，但可以通过放置 AUS 来控制。替代的开放式手术重建选择也有类似的局限性，可能有更大的发病率。
